At active dose levels (≥ 50 µg/kg), 26 of 33 evaluable patients (79%) achieved objective responses, including stringent or complete remissions in 30%, the company said.

Aptose Presents Safety, Response, and MRD Clinical Data from TUSCANY Phase 1/2 Clinical Trial of Tuspetinib Triplet Therapy in Newly Diagnosed AML at the 2025 EHA Congress.

Most totally blind people have circadian rhythms that are “free-running” (i.e., that are not synchronized to environmental time cues and that oscillate on a cycle slightly longer than 24 hours).

A pathological complete response to treatment (in the breast and nodes) occurred in 78.2% of patients; 57.7% underwent a lumpectomy, 42.3% underwent a mastectomy, and 55.4% underwent sentinel ...

All responders remain in response as of a median 8.5 month follow-up, with a median time to first response of 1.2 months. The Phase I trial, initiated in November 2022, has enrolled 126 patients ...

Owing to the toxic potential of unfolded proteins, their accumulation in the endoplasmic reticulum activates a cellular stress response. This unfolded protein response remodels the secretory ...

This repository provides unofficial binary wheels for open-source extension packages for Python on Windows, linked to the Intel(r) oneAPI Math Kernel Library (oneAPI MKL). The files are unofficial ...

Maximum gain from combining multiple high-power signals is achieved by equalising both the amplitude and phase of the combination. Achieving in-phase and equal amplitude power combining with ...

Phase response analysis of light-perturbed closed and aging Ru-catalyzed Belousov−Zhabotinsky (BZ) reactions with malonic, methyl-, ethyl-, butyl-, and phenylmalonic acids as organic substrates ...